Demerol 100 mg tablets (Meperidine hydrochloride) belongs to the class of medications known as narcotic analgesics (pain relievers).
Demerol 100 Mg (Meperidine Hydrochloride)
€190.00 – €610.00
Demerol 100 mg (Meperidine hydrochloride)
Demerol 100 mg tablets (Meperidine hydrochloride) belongs to the class of medications known as narcotic analgesics (pain relievers). Demerol 100 mg tablets (Meperidine hydrochloride) is used to treat moderate-to-severe pain associated with many medical, surgical, obstetrical, and dental procedures.
Demerol 100 mg tablets (Meperidine hydrochloride) works to decrease pain by acting on the brain to increase pain tolerance.Demerol 100 mg tablets (Meperidine hydrochloride) works very quickly and will usually begin to relieve pain within 15 minutes. This medication should not be used to treat chronic pain.
Demerol 100 mg tablets (Meperidine hydrochloride) is contraindicated for use in patients with significant respiratory depression and in patients with acute or severe asthma (e.g., status asthmaticus) in unmonitored care settings or in the absence of resuscitative equipment. Additionally, avoid coadministration with other CNS depressants when possible, as this significantly increases the risk for profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate; if concurrent use is necessary, use the lowest effective dosages and minimum treatment durations needed. Monitor patients closely for signs or symptoms of respiratory depression and sedation. In patients with chronic obstructive pulmonary disease (COPD), cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, respiratory insufficiency, upper airway obstruction, or preexisting respiratory depression, it is recommended that non-opioid analgesics be considered as alternatives to meperidine, as even usual therapeutic doses may decrease respiratory drive and cause apnea in these patient populations. Extreme caution should also be used in patients with chronic asthma, kyphoscoliosis (a type of scoliosis), hypoxemia, or paralysis of the phrenic nerve.
Patients with advanced age, debilitation, or sleep apnea are at an increased risk for the development of respiratory depression associated with meperidine. Use with caution in patients with obesity as this is a risk factor for obstructive sleep-apnea syndrome and/or decreased respiratory reserve. Meperidine should not be used during impaired consciousness or coma, as significant decreases in respiratory drive may lead to adverse intracranial effects from carbon dioxide retention. Respiratory depression, if left untreated, may cause respiratory arrest and death. Symptoms of respiratory depression include a reduced urge to breathe, a decreased respiratory rate, or deep breaths separated by long pauses (a “sighing” breathing pattern). Carbon dioxide retention from respiratory depression may also worsen opioid sedating effects. Careful monitoring and dose titration is required, particularly when CYP450 3A4 inhibitors or inducers are used concomitantly; concurrent use of a CYP3A4 inhibitor or discontinuation of a concurrently used CYP3A4 inducer may increase plasma meperidine concentrations and potentiate the risk of fatal respiratory depression.
100 Tablets, 200 Tablets, 300 Tablets, 500 Tablets